Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 302

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 302
---
 | ) |
| Balance as of June 30, 2024   |     | $ |  148 |   |

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES |

| 1. | Between September 2004                                                                                                              
 and December 2015, the Company received funding from the IIA for its participation in certain research and development activities,  
 based on budgets approved by the IIA, subject to the fulfillment of specified milestones. The Company is committed to pay royalties 
 to the IIA on proceeds from sale of products related to research and development activities of which the IIA participates by way of 
 grants. According to the funding terms, royalties between 3% and 4.5% are payable on sales of developed products funded, up to 100% 
 of the grant received by the Company, linked to U.S. dollar and bearing Term SOFR interest rate. In the case of failure of a funded 
 research and development activity, the Company is not obligated to pay any such royalties to the IIA. As of June 30, 2025, total    
 contingent obligation to IIA is approximately $2,685 (including interest at approximately the amount of $340).                      |

<div align='center'>F-44</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

| 2. | In February 2018, the                                                                                                                
 Company entered into a services agreement with Baxter Healthcare Corporation (the “Baxter Services Agreement” and “Baxter”,          
 respectively), pursuant to which the Company agreed to purchase certain services from Teva Medical (Marketing) Ltd. (“Teva”)         
 in connection with GelrinC. In April 2022, we amended the Baxter Services Agreement to replace Teva as the supplier of Tisseel under 
 the Supply Agreement for GelrinC with Baxter as Teva ceased to distribute Tisseel in Israel.                                         |

Under the Baxter Services Agreement,
Baxter provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for
all such support. In consideration for receiving such support, the Company pays Baxter $60 per year until the Company received Food and
Drug Administration (the “FDA”) approval to market GelrinC in the